Anti-thyroid drugs decrease mucosal damage in a rat model of experimental colitis

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 2, 1997, Pages 341-345

  Oren, R ^a,c   Maaravi, Y ^a   Karmeli, F ^a   Kenet, G ^b   Zeidel, L ^b   Hubert, A ^a   Eliakim, R ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c Ichilov Medical Center   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; PROPYLTHIOURACIL; THIAMAZOLE; THYROTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; COLON MUCOSA; HYPOTHYROIDISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030945418     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.127299000.x     Document Type: Article

References (19)

1. Singer DS, Kohn LD, Zinger H, Mozes E. Methimazole prevents induction of experimental systemic lupus erythematosus in mice. J Immunol 1994; 153(2): 873-80.
2. Greco DS, Harpold LM. Immunity and the endocrine system. Vet Clin North Am Small Anim Pract 1994; 24(4): 765-82.
3. Volper R. Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actins on the thyroid cell, modulating thyrocyte-immunocyte signalling: a review. Thyroid 1994; 4(2): 145-6.
4. Saji M, Moriarty J, Ban T, Singer DS, Kohn LD. MHC class I expression in rat thyroid cells is regulated by hormones, methimazole and iodide as well as interferon. J Clin Endocrinol Metab 1992; 75: 871-8.
5. Kirsner JD, Shorter RG. Recent developments in non-specific inflammatory bowel disease. N Engl J Med 1982; 306: 775-85, 837-48.
6. MacDermott RP, Stenson WF. The role of the immune system in inflammatory bowel disease. Immunol Allerg Clin N Am 1988; 8: 521-42.
7. MacDermott RP, Stenson WF. Alterations of the immune system in ulcerative colitis and Crohn's disease. Adv Immunol 1988; 42: 285-328.
8. Mayer L. Mucosal immune system in inflammatory bowel disease. In: MacDermott, RP, Stensen, WF eds. Inflammatory Bowel Disease. New York: Elsevier, 1992: 53-75.
9. Okazaki K, Morita M, Nishimori I, et al. Major histocompatability antigen-restricted cytotoxicity in Inflammatory bowel disease. Gastroenterology 1993; 104: 384-91.
10. Karmeli F, Eliakim R, Okon E, Rachmilewitz D. Gastric mucosal damage is mediated by substance P and prevented by ketotifen. Gastroenterology 1991; 100: 1206-16.
11. Morris GP, Beck PI, Henidge MS, Depew WI, Szwezcuk MR, Wallace JI. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803.
12. Kawasaki T, Carmichael FJ, Giles G, Saldivia V, Israel Y, Orrego H. Effects of propylthiouricil and methimazole on splanchnic hemodynamics in awake and restrained rats. Hepatology 1989; 10: 273-8.
13. Wallace JL, Braquet P, Ibbotson GC, MacNaughton WK, Cirino G. Assessment of the role of platelet activating factor in an animal model of inflammatory bowel disease. J Lipid Med 1989; 1: 13-23.
14. Bradley PP, Pirebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermat 1982; 78: 206-9.
15. Rachmilewitz D, Simon PL, Schwartz IW, Griswold DE, Fondacaro JD, Wasserman MA. Inflammatory mediators of experimental colitis in rats. Gastroenterology 1989; 97: 326-37.
16. Jarnerot G, Khan A, Truelove S. The thyroid in ulcerative colitis and Crohn's disease. II. Thyroid enlargement and hyperthyroidism in ulcerative colitis. Acta Med Scand 1975; 197: 83-7.
17. Oren R, Hilzenrat N, Maaravi Y, Sikuler E. Hemodynamic effects of hypothyroidism induced by Methimazole in normal and portal hypertensive rats. Digest Dis Sci 1995; 40: 1941-5.
18. Oren R, Shirin H, Dotan I, et al. Hypothyroidism inhibits experimentally induced acute T cell dependent hepatic damage in mice. J Hepatol 1995; 23(1): 213A (Abstract).
19. Schwedes U, Wdowinski JM, Siede WH, Vardarli I, Schmidt R, Usadel KH. Effect of hypometabolism on cell injury. Klin Wochenschr 1986; 64(VII): 146-8.